Shilpa Medicare informs about approval for tablets

16 Sep 2022 Evaluate
Shilpa Medicare has informed that the Company has received U.S Food and Drug Administration tentative approval for its ANDA, Tenofovir Alafenamide Tablets, 25 mg on 15 Sep 2022. The ANDA was filed as 'First to File' submission on NCE -1 date. Tenofovir Alafenamide Tablets, 25 mg is a generic equivalent of reference listed drug (RLD) Vemlidy® tablets, of Gilead Sciences Inc. used in the treatment of chronic hepatitis B virus infection as recommended in the label approved by FDA. According to IQVIA MAT Q2 2022 data, the US market for Tenofovir Alafenamide Tablets, 25 mg is approximately $498.14 Million.

The above information is a part of company’s filings submitted to BSE.

Shilpa Medicare Share Price

263.45 -7.20 (-2.66%)
23-Jan-2026 13:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1636.60
Dr. Reddys Lab 1239.35
Cipla 1328.35
Zydus Lifesciences 885.30
Lupin 2141.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×